Filter
141
Filtered Results: 141
Text search:
delamanid
Featured
Recommendations
25
New Publications
37
Language
Document type
No document type
90
Guidelines
21
Studies & Reports
12
Manuals
8
Training Material
4
Fact sheets
3
Situation Updates
2
Infographics
1
Countries / Regions
Western and Central Europe
15
Eastern Europe
11
Germany
4
India
3
Bolivia
3
Ethiopia
2
South Africa
2
Argentina
2
South–East Asia Region
2
Eastern Europe and Central Asia
2
Asia
2
Russia
2
Zambia
1
Turkey
1
Malawi
1
Namibia
1
Brazil
1
Ukraine
1
Colombia
1
Botswana
1
Latin America and the Carribbean
1
Paraguay
1
Tajikistan
1
Estonia
1
Romania
1
Georgia
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
37
Countries
24
Pharmacy & Technologies
3
Public Health
2
Key Resources
1
Toolboxes
TB
118
HIV
7
Pharmacy
4
Caregiver
3
AMR
2
COVID-19
2
Ebola
1
Polio
1
Refugee
1
Global Health Education
1
NTDs
1
Information für Ärzte.
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have be...
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and ... in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
Accessed November 2017
Report of a mission 20–24 April 2015
Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...
Framework for implementation.
The END TB Strategy.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
